LifeCell makes regenerative tissue products that are commonly used in breast reconstruction procedures and complex hernia surgeries to provide soft tissue support.

Allergan Chief Executive Brent Saunders has ‘s deal to sell itself last ydescribed the company’s acquisition strategy as being one of “stepping stones.” Allerganear to Pfizer Inc. for US$160 billion was dropped due to a change in tax law.

Allergan, best known for its Botox product, said LifeCell’s 2016 sales are expected to be US$450 million and grow at a mid-single digit rate. It expects the deal to close in the first half of 2017.

Dublin-based Allergan, which was created through the combination of Actavis and Allergan, earlier this year sold its generics business to Teva Pharmaceutical Industries, freeing up cash for deals.

Allergan has agreed to 12 deals this year, including the US$1.7 billion acquisition of Tobira Therapeutics Inc., maker of an experimental treatment for fatty liver disease, and US$639 million acquiring Vitae, maker of an experimental drug to treat psoriasis.

The exhaustive work, priced at 78 yuan took Shi Li, a deaf woman who serves as deputy head of the Provincial Association of Deaf People and her disabled husband Cui Jiping, six years and cost over a million yuan to compile.

“(Before reading the book) I never imagined that there were records about the culture of deaf people dating back as early as the Warring
States period (475BC to 221BC), and there were laws specially made to protect our rights,” said WAng Hongqing, a deaf man in his 50s.

“The book shows that we’re not alone, since it presents so many exchanges between the deaf across the world,” Wang said.

The encyclopaedia provides the deaf with a rational perspective on themselves and can help ordinary people know more about the group, which is significant in building a discrimination-free society, a senior official with the China Distabled People Union aid in a congratulatory letter sent to the couple.

Source: The Star

“The decision to further develop this successful research collaboration underlines Bayer’s commitment to China as an important component of our innovation strategy,” said Prof. Dr. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery.

Headed by Dr. Shi Yigong, Professor and Dean of School of Life Sciences, Tsinghua University, multiple joint research projects have been initiated at the BTC which was established by Bayer HealthCare and Tsinghua University in 2009.

The joint projects focus on different research aspects starting from early research programs to gain deeper understanding of disease mechanisms, identification of new drug targets and spanning further to joint structural biology research and medicinal chemistry programs.

“A new focus of our collaboration will be the area of structural biology, where scientists from Tsinghua University will work in close collaboration with Bayer scientists to solve the 3D protein structure of biological molecular targets as a basis for new drug discovery projects,” said Dr. Shi, a renowned structural biologist.

To further strengthen the relationship between Bayer and Tsinghua University, a Bayer endowed chair at the Tsinghua University – Institute of Biomedicine will be established in 2012, with Dr. Dong Chen as the first chair.

“The Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery has established itself as an interface to foster communication between leading experts from Tsinghua University’s Institute of Biomedicine and researchers from Bayer HealthCare,” said Prof. Yuan Si, vice president of Tsinghua University.

Siriraj hospital is the country’s oldest public and teaching hospitals subsidised by the government. It receives about US$49 million per year, as it has to bear the cost derived from general patent treatments, which results in an operating loss amount to 10% of income.

Building and equipping the new hospital is estimated to reach a total of US$294.2 million. SiPH is expected to break even in three years and start earning for the next five to six years to cover its overall investment costs. Profits are expected to be reaped within the eighth or ninth year.

“The new hospital will serve as an alternative quality healthcare service for patients with the ability to pay, by using our strong points of high-quality treatment, experienced doctors and medical excellence to attract new patients,” Panchavinnin said.

He added that service fees would be higher than those offered at Siriraj Hospital, but as much as 20% to 25% lower than at other private hospitals. Treatment services will cover both general and complicated diseases.

Health Care Asia
Home